News | EP Mapping and Imaging Systems | October 09, 2019

Acutus Medical and Innovative Health Collaborate to Increase Patient Access to Electrophysiology Care

Companies will enter a partnership that offers hospitals Acutus technology together with regulated reprocessing of single-use devices

Acutus Medical and Innovative Health Collaborate to Increase Patient Access to Electrophysiology Care

October 9, 2019 — Acutus Medical and Innovative Health announced a partnership that will offer advanced electrophysiology technology to improve patient outcomes in a cost-efficient manner. The two high profile venture-backed companies will team to offer hospital customers a comprehensive suite of EP products, including Acutus’ next-generation EP mapping and accessory products together with a growing portfolio of reprocessed single-use EP devices from a range of manufacturers.

Acutus will also work proactively with Innovative Health to gain clearances, as appropriate, to market reprocessed versions of certain proprietary Acutus products – a highly novel approach for a venture-backed device company. The goal of the partnership is to simultaneously rein in per-procedure costs while freeing up hospital budget dollars for emerging new technologies that hold the prospect of improving clinical outcomes and speeding up procedure times.

Recognizing the constraints that hospitals and health systems face in delivering quality patient care at a sustainable cost is fundamental in the current healthcare environment.  Safe, proven and effective reprocessing of high-cost single-use devices offers a reliable avenue for hospitals to combine the best of both worlds: best-in-class, state-of-the-art technologies together with cost-effective, sustainable per-procedure costs.

Acutus provides a full suite of technologies and products for electrophysiology diagnostic and ablation procedures through an open platform that enables personalized and adaptive approaches to arrhythmia therapy.  

Innovative Health is a specialty EP reprocessing company that collects, reprocesses and returns single-use labeled EP catheters to hospitals, reducing each atrial fibrillation (AF) procedure’s device costs by as much as 30 percent. The company holds formal U.S. Food and Drug Administration (FDA) clearances to reprocess many high-complexity EP devices, such as mapping catheters, diagnostic ultrasound catheters and introducer sheaths. This allows Innovative Health hospital partners to increase their savings compared to other reprocessing programs. 

For more information: www.acutusmedical.com, www.innovative-health.com

Related Content

The Farapulse pulsed field ablation (PFA) system, also referred to as electroporation,  ablates heart tissue using the creation of an electric field instead of using thermal energy sources such as radiofrequency ablation or cryoablation.

The Farapulse pulsed field ablation (PFA) system ablates heart tissue using the creation of an electric field instead of using thermal energy sources such as radiofrequency ablation or cryoablation.
 

News | EP Lab | September 23, 2020
September 23, 2020 — Boston Scientific Corp.
A conformal array of flexible electrodes affixed to an inflated balloon catheter. The sensors have the ability to make measurements of temperature, force of contact and electrophysiological parameters, ability to customize diagnostic and therapeutic functions and offer real-time feedback. Photo by John Rogers, Northwestern University.

A conformal array of flexible electrodes affixed to an inflated balloon catheter. The sensors have the ability to make measurements of temperature, force of contact and electrophysiological parameters, ability to customize diagnostic and therapeutic functions and offer real-time feedback. Photo by John Rogers, Northwestern University.

News | EP Lab | September 08, 2020
September 8, 2020 — Researchers developed a new class of medical instruments equipped with an advanced soft electroni
Biosense Webster's Carto Prime Mapping Module offers new tools to help shorten ablation time. Left is an example of Coherent imaging showing conduction identification, conduction velocity vectors and conduction barrier zones. Top right, Carto Finder Module automatic visualization of region of interest. Below right, LAT Hybrid imaging, showing correct identification of PVC location based on catheter location in sinus rhythm, and automated visualization of PVC points.

Biosense Webster's Carto Prime Mapping Module offers new tools to help shorten ablation time. Left is an example of Coherent imaging showing conduction identification, conduction velocity vectors and conduction barrier zones. Top right, Carto Finder Module automatic visualization of region of interest. Below right, LAT Hybrid imaging, showing correct identification of PVC location based on catheter location in sinus rhythm, and automated visualization of PVC points.

News | EP Lab | September 03, 2020
September 3, 2020 – Biosense Webster launched its Carto 3 System Version 7 and the Carto Prime Mapping Module to enha
HRS study finds Frequent Coffee Consumption Lowers Chance of Arrhythmias. #HRS #HRS20 Heartrhythm20
News | EP Lab | May 28, 2020
May 28, 2020 – A recent study revealed that drinking a couple of cups of coffee per day does not lead to a greater ri
he Actus AcQMap EP 3-D mapping catheter used  to speed  electromapping and procedure times.

he Actus AcQMap EP 3-D mapping catheter used  to speed  electromapping and procedure times.

News | EP Lab | May 20, 2020
May 20, 2020 — Acutus Medical and Biotronik announced a new alliance to provide a comprehensive portfolio of...
Thermedical, a developer of thermal-ablation medical systems to treat ventricular tachycardia (VT), announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its Saline Enhanced Radiofrequency (SERF) Ablation system and Durablate catheter.
News | EP Lab | May 19, 2020
May 19, 2020 – Thermedical, a developer of thermal-ablation medical systems to treat ventricular tachycardia (VT), an
HRS presentations included BlueSync Evaluation study for Medtronic MyCareLink Heart mobile app and Micra TPS CED Study
News | EP Lab | May 14, 2020
May 14, 2020 – Medtronic announced results from late-breaking clinical trials evaluating the MyCareLink Heart mobile